CUGENE
Cugene develop medicines that harness the power of the human immune system to fight disease. Through innovative bioengineering, these novel therapeutics will provide specificity and efficacy while limiting unwanted side effects on neighboring healthy tissues.
CUGENE
Social Links:
Industry:
Biotechnology Health Care Medical
Founded:
2016-01-01
Address:
Waltham, Massachusetts, United States
Country:
United States
Website Url:
http://www.cugene.com
Total Employee:
11+
Status:
Active
Contact:
+1 781 893 5800
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
Fischer Imaging
Fischer Imaging develops mammography systems for breast imaging.
medilabo RFP
Medilab RFP focuses on designing and developing innovative medicine for neurodegenerative disorders.
Piramed
Piramed Limited, a biotech company, discovers and develops new medicines for the treatment of cancer and immune inflammatory disorders.
SENS Foundation
SENS Research Foundation is focused on research and development regenerative medicine for age-related diseases.
Official Site Inspections
http://www.cugene.com Semrush global rank: 5.62 M Semrush visits lastest month: 1.5 K
- Host name: 16.110.212.35.bc.googleusercontent.com
- IP address: 35.212.110.16
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Cugene"
Cugene - Crunchbase Company Profile & Funding
Cugene develop medicines that harness the power of the human immune system to fight disease. Through innovative bioengineering, these novel therapeutics will provide specificity and …See details»
Investors - Cugene
Oct 8, 2021 Cugene is actively seeking partnerships to advance our programs and are open to various collaboration models, including licensing, acquisition, or co-development opportunities. …See details»
Cugene Inc. | LinkedIn
Cugene Inc. | 3,794 followers on LinkedIn. One Passion, One Goal, Many Cures. | Cugene is a clinical-stage biotechnology company focused on developing next-generation precision immunology and ...See details»
Cugene Company Profile 2024: Valuation, Funding
Information on valuation, funding, acquisitions, investors, and executives for Cugene. Use the PitchBook Platform to explore the full profile.See details»
Contact - Cugene
Cugene is a Boston-based, clinical-stage biotechnology company dedicated to developing next-generation medicines for the treatment of cancer and autoimmune diseases.See details»
Cugene Inc. - VentureRadar
"Cugene is a clinical-stage biotechnology company focused on developing next-generation precision immunology and oncology medicines that harness specific immune cells to treat …See details»
Cugene - Updates, News, Events, Signals & Triggers
Cugene may be growing as it has secured an upfront payment of $48.5 million, which indicates a significant financial injection and potential for further development. This upfront payment is …See details»
Cugene - Crunchbase
Cugene, Innovate Biopharmaceuticals, CEL-SCI, Chimeron Bio, Adiso Therapeutics, and Immetas operate in the biotechnology and pharmaceutical sector. Innovate, CEL-SCI, …See details»
Cugene Company Profile - Office Locations, Competitors, Revenue ...
Cugene has 5 employees at their 1 location. See insights on Cugene including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Cugene - Work in biotech
Cugene is a clinical-stage biotech founded in 2016 and based in Waltham Massachusetts. The team is developing next-generation therapeutics for cancer and autoimmune disease. Their …See details»
AbbVie and Cugene Announce Collaboration in Autoimmune …
May 16, 2022 Cugene is a clinical-stage biotechnology company focused on developing next-generation precision immunology and oncology medicines to treat autoimmune disease and …See details»
AbbVie and Cugene Announce Collaboration in Autoimmune …
May 17, 2022 AbbVie (NYSE: ABBV) and Cugene Inc., a clinical-stage biotechnology company focused on developing next-generation precision immunology and oncology medicines to treat …See details»
Cugene - Contacts, Employees, Board Members, Advisors & Alumni
Cugene discover and develop innovative medicines for treating cancer and inflammatory disorders.See details»
Current Openings - Cugene
At Cugene, our workplace reflects the value of diversity and inclusion and we recognize each employee as an integral part of our success. CUGENE Inc is an equal opportunity employer …See details»
AbbVie, Cugene Ink Licensing Pact For Autoimmune
May 16, 2022 AbbVie Inc (ABBV) and Cugene Inc have announced an exclusive worldwide license option agreement for CUG252 for the potential treatment of autoimmune and …See details»
AbbVie and Cugene Announce Collaboration in Autoimmune …
May 16, 2022 Cugene is a clinical-stage biotechnology company focused on developing next-generation precision immunology and oncology medicines to treat autoimmune disease and …See details»
AbbVie and Cugene Announce Collaboration in Autoimmune …
AbbVie and Cugene Inc., a clinical-stage biotechnology company focused on developing next-generation precision immunology and oncology medicines to treat autoimmune disease and …See details»
Cugene Receives FDA Approval for Phase 1a Healthy Volunteer …
Cugene is launching its first-in-human study for subcutaneously administered CUG252 in healthy volunteers, evaluating its safety, tolerability, pharmacokinetics and pharmacodynamics.See details»
News - Cugene
Cugene presents promising preclinical data on VitoKine-2, a precision-engineered tumor-activable IL-2 therapeutic designed to target tumor-infiltrating lymphocytes (TIL) in the tumor …See details»